BLISS GVS PHARMA LTD. - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure<BR> Requirements) Regulations, 2015 For Setting Up "New State Of The Art Oral Solid Dosage<BR> Facility".
Download
|
< Back
|
16 Mar 2020
|
Pursuant to Regulation 30(6) read with Para B of Part A of Schedule III of SEBI (Listing Obligations<BR> and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has<BR> completed the commissioning &. qualification of Phase-I for its new state of the art multi-product<BR> facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the Company<BR> in terms of planned production capacity when completed. Itis equipped with state of the art process<BR> equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention.
|
View all announcements for BLISS GVS PHARMA LTD.
|
Source:
BSE India
|